Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of PRAME knockdown in SKOV3 and ES2 ovarian cancer cells

ABSTRACT: This study investigated transcriptomic alterations following PRAME knockdown in ovarian cancer cells. SKOV3 and ES2 cells were transfected with PRAME-targeting small interfering RNA (siPRAME) or negative-control siRNA (siNC), followed by bulk RNA sequencing. Three biological replicates were included for each condition in each cell line. Differential expression and pathway enrichment analyses were performed to characterize transcriptional programs associated with PRAME knockdown and to explore potential downstream molecular mechanisms of PRAME in ovarian cancer cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE347479 | GEO | 2026/09/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic profiling of PRAME knockdown in SKOV3 and ES2 ovarian cancer cells

Project description:Transcriptomic profiling of PRAME knockdown in SKOV3 and ES2 ovarian cancer cells

| PRJNA1530341 | ENA

Effect of knockdown RUNX1-IT1 on gene expression in ES2 cells

Project description:To investigate the function of RUNX1-IT1 in ovarian cancer progression, we constructed ES2 cell lines with knockdown of RUNX1-IT1 and the control group. We then performed gene expression profiling analysis using data obtained from RNA-seq of 2 different cells.

2024-01-01 | GSE245778 | GEO

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

Project description:Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient population, more TCRs targeting peptides derived from different TAAs binding in various HLA class I molecules are essential. By performing a differential gene expression analysis using mRNA-seq datasets, PRAME, CTCFL and CLDN6 were selected as strictly tumor-specific TAAs, with high expression in ovarian cancer and at least 20-fold lower expression in all healthy tissues of risk. In primary OVCA patient samples and cell lines we confirmed expression and identified naturally expressed TAA-derived peptides in the HLA class I ligandome. Subsequently, high-avidity T-cell clones recognizing these peptides were isolated from the allo-HLA T-cell repertoire of healthy individuals. Three PRAME TCRs and one CTCFL TCR of the most promising T-cell clones were sequenced, and transferred to CD8+ T cells. The PRAME TCR-T cells demonstrated potent and specific antitumor reactivity in vitro and in vivo. The CTCFL TCR-T cells efficiently recognized primary patient-derived OVCA cells, and OVCA cell lines treated with demethylating agent 5-aza-2′-deoxycytidine (DAC). The identified PRAME and CTCFL TCRs are promising candidates for the treatment of patients with ovarian cancer, and are an essential addition to the currently used HLA-A*02:01 restricted PRAME TCRs. Our selection of differentially expressed genes, naturally expressed TAA peptides and potent TCRs can improve and broaden the use of T-cell therapies for patients with ovarian cancer or other PRAME or CTCFL expressing cancers.

2023-03-10 | PXD040651 | Pride

The whole transcriptome expression profiling comparison between the CtBP1 knockdown, CtBP2 knockdown and scramble control in ovarian cancer SKOV3 cells

Project description:To discover the core gene expression features of CtBP1, CtBP2 differently regulated in ovarian cancer SKOV3 cells. The compared the whole transcript expression profiling between CtBP1 knockdown, CtBP2 knockdown and scramble control in ovarian cancer skov3 cells.

2017-08-31 | GSE60251 | GEO

RNAseq of SKOV3(AA) and SKOV3(CC)

Project description:To study the effect of rs1192691 on ovarian cancer cells, we generated SKOV3(CC) from SKOV3(A/A) using CRISPR/Cas9 technology and performed RNA-seq.

2022-01-18 | GSE181884 | GEO

RNA-seq profiling of PRAME knockdown in A375SM skin cutaneous melanoma cells

Project description:This study investigates the transcriptomic effects of PRAME knockdown in the A375SM skin cutaneous melanoma cell line. Cells were transduced with either control shRNA (shCtrl) or PRAME-targeting shRNA (shPRAME), followed by paired-end RNA sequencing. The dataset provides gene expression changes associated with PRAME silencing and offers insights into PRAME-regulated pathways in melanoma.

2025-12-31 | GSE311500 | GEO

Transcriptome profiling of A375SM melanoma cells following PRAME and BAP1 knockdown

Project description:To investigate the transcriptomic changes associated with PRAME and BAP1 knockdown, RNA-seq was performed on A375SM melanoma cells stably expressing shRNA targeting PRAME (shPRAME), BAP1 (shBAP1), or a non-targeting control (shEmpty). This study aims to understand the role of PRAME and BAP1 in gene regulation and melanoma progression.

2025-09-02 | GSE306132 | GEO

Determination of CNVs in SKOV3 cells knocked down in BECN1 or MAP1LC3B

Project description:SKOV3 ovarian cancer cells have high basal autophagy levels and were used as a model cell line to enable knockdown of autophagy genes and study the changes of DNA copy number as a consequence of impaired autophagy.

2019-12-16 | GSE122433 | GEO

Sequencing in transcriptomes in Ovarian cancer cell line SKOV3 and bevacizumab-treated SKOV3

Project description:To investigate the possible mechanism of bevacizumab resistance in ovarian cancer ,we examined the changes in gene expression of SKOV3 before and after bevacizumab intervention. Results provide insight into molecular mechanisms of acquired resistance to bevacizumab in ovarian cancer.

2023-12-31 | GSE165419 | GEO

Expression data from ovarian cancer SKOV3 human cell line

Project description:CDCP1 and PLAGL2 have been shown to act as oncogenes in several cancer types but little is known about the molecular signalling underlying these processes in ovarian cancer cells. In this study we aim to find the downstream signalling upon their individual silencing in the human ovarian cancer cell line SKOV3. We used microarrays to detail the global programme of gene expression underlying CDCP1 and PLAGL2 signalling in the human ovarian cancer cell line SKOV3

2020-04-12 | GSE113115 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data